In the chronic disease state, reflected by profound remodeling of the pulmonary arteries, ETB, however, may play a less prominent role, as indicated by the fact that ETA-selective blockers do not appear to be superior to dual ETA/ETB therapy in established PAH (77, 78). The gene discussed is EDNRA; the disease is pulmonary arterial hypertension.